Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

444 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study.
Ebina K, Hashimoto M, Yamamoto W, Ohnishi A, Kabata D, Hirano T, Hara R, Katayama M, Yoshida S, Nagai K, Son Y, Amuro H, Akashi K, Fujimura T, Hirao M, Yamamoto K, Shintani A, Kumanogoh A, Yoshikawa H. Ebina K, et al. PLoS One. 2018 Mar 15;13(3):e0194130. doi: 10.1371/journal.pone.0194130. eCollection 2018. PLoS One. 2018. PMID: 29543846 Free PMC article.
Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.
Hashimoto M, Furu M, Yamamoto W, Fujimura T, Hara R, Katayama M, Ohnishi A, Akashi K, Yoshida S, Nagai K, Son Y, Amuro H, Hirano T, Ebina K, Uozumi R, Ito H, Tanaka M, Ohmura K, Fujii T, Mimori T. Hashimoto M, et al. Among authors: ebina k. Arthritis Res Ther. 2018 Aug 3;20(1):165. doi: 10.1186/s13075-018-1673-1. Arthritis Res Ther. 2018. PMID: 30075810 Free PMC article.
Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.
Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, Onishi A, Nagai K, Son Y, Amuro H, Yamamoto K, Maeda Y, Murata K, Jinno S, Takeuchi T, Hirao M, Kumanogoh A, Yoshikawa H. Ebina K, et al. Arthritis Res Ther. 2019 Apr 11;21(1):91. doi: 10.1186/s13075-019-1880-4. Arthritis Res Ther. 2019. PMID: 30971306 Free PMC article.
Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.
Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, Onishi A, Nagai K, Son Y, Amuro H, Yamamoto K, Maeda Y, Murata K, Jinno S, Takeuchi T, Hirao M, Kumanogoh A, Yoshikawa H. Ebina K, et al. Arthritis Res Ther. 2019 May 6;21(1):114. doi: 10.1186/s13075-019-1897-8. Arthritis Res Ther. 2019. PMID: 31060597 Free PMC article.
Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study.
Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, Onishi A, Nagai K, Son Y, Amuro H, Yamamoto K, Maeda Y, Murata K, Jinno S, Takeuchi T, Hirao M, Kumanogoh A, Yoshikawa H. Ebina K, et al. PLoS One. 2019 May 8;14(5):e0216624. doi: 10.1371/journal.pone.0216624. eCollection 2019. PLoS One. 2019. PMID: 31067271 Free PMC article.
Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.
Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K, Takeuchi T, Nagai K, Son Y, Amuro H, Onishi A, Jinno S, Hara R, Katayama M, Yamamoto K, Kumanogoh A, Hirao M. Ebina K, et al. Clin Rheumatol. 2020 Sep;39(9):2563-2572. doi: 10.1007/s10067-020-05015-5. Epub 2020 Mar 11. Clin Rheumatol. 2020. PMID: 32162152
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study.
Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K, Takeuchi T, Shiba H, Son Y, Amuro H, Onishi A, Akashi K, Hara R, Katayama M, Yamamoto K, Kumanogoh A, Hirao M. Ebina K, et al. Arthritis Res Ther. 2020 Jun 15;22(1):142. doi: 10.1186/s13075-020-02232-w. Arthritis Res Ther. 2020. PMID: 32539813 Free PMC article.
Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study.
Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K, Onishi A, Jinno S, Hara R, Son Y, Amuro H, Takeuchi T, Yoshikawa A, Katayama M, Yamamoto K, Hirao M, Okita Y, Kumanogoh A, Nakata K. Ebina K, et al. Clin Rheumatol. 2021 Jul;40(7):2673-2680. doi: 10.1007/s10067-021-05609-7. Epub 2021 Jan 29. Clin Rheumatol. 2021. PMID: 33515115
444 results